Skip to main content
Premium Trial:

Request an Annual Quote

Santaris, Pfizer Expand LNA Drug Collaboration


Santaris Pharma said this week that its worldwide strategic alliance with Pfizer has been expanded, triggering a $14 million payment from the big pharma for access to Santaris' locked nucleic acid technology for the development of RNA-targeting drugs.

The deal was first struck in 2009 between Santaris and Wyeth (GSN 1/15/2009). Under the terms of the deal, Wyeth was to select up to 10 targets against which Santaris would create LNA-based drug candidates, although a Wyeth official told Gene Silencing News at the time that the company had no plans to pursue microRNA targets.

Pfizer inherited the partnership when it acquired Wyeth late in 2009.

Under the terms of the expanded arrangement, Santaris stands to receive up to $600 million in milestones, plus royalties, on products developed through the collaboration.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.